News
-
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Bayer Aktiengesellschaft: Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
Bayer announces positive results from Phase III OCEANIC-STROKE study, showing asundexian reduces ischemic stroke risk with antiplatelet therapy -